Q-omics provides the consensus-scored TRAV18 profile across patient tissues and cancer cell-line models. TRAV18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TRAV18 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, TRAV18 RNA expression shows 14,304 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KICH, and TGCT as cancer lineages where TRAV18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV18 survival associations across molecular data types. TRAV18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV18 RNA expression–survival associations across cancer types. High TRAV18 expression shows unfavorable associations in UVM, but favorable associations in BRCA, SKCM, HNSC, BLCA and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TRAV18 RNA expression.
This table summarizes TRAV18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV18 shows lower tumor expression in COAD and higher tumor expression in KICH, KIRC, BRCA, LUAD and THCA. The KICH box plot shows higher TRAV18 RNA expression in tumor versus normal tissue (log2 FC = +1.601, t-test p < 0.001).
This table shows molecular features associated with TRAV18 in patient tissues and cancer cell lines. In patient samples, TRAV18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
